Which has better valuation and earnings, HIND or IMA?

Vyome has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vyome $320K 44.09 -$10.26M -$3.37 N/A ImageneBio $800K 69.06 -$45.35M -$4.58 N/A

Is HIND or IMA more profitable?

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% ImageneBio N/A -38.99% -34.84%

Does the media favor HIND or IMA?

In the previous week, Vyome and Vyome both had 1 articles in the media. Vyome's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImageneBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate HIND or APLM?

Vyome presently has a consensus price target of $9.25, indicating a potential upside of 360.20%. Given Vyome's stronger consensus rating and higher possible upside, equities analysts clearly believe Vyome is more favorable than Apollomics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, HIND or APLM?

Vyome has higher earnings, but lower revenue than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vyome $320K 44.09 -$10.26M -$3.37 N/A Apollomics $8.50M 7.89 -$10.94M N/A N/A

Is HIND or APLM more profitable?

Apollomics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Apollomics' return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Vyome -3,024.84% -197.33% -138.14% Apollomics N/A N/A N/A

Is ELTX or HIND more profitable?

Elicio Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Vyome -3,024.84% -197.33% -138.14%

Does the media prefer ELTX or HIND?

In the previous week, Elicio Therapeutics had 2 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Vyome. Elicio Therapeutics' average media sentiment score of 0.34 beat Vyome's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TVGN or HIND?

Vyome has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.63 N/A Vyome $320K 44.09 -$10.26M -$3.37 N/A

Is TVGN or HIND more profitable?

Tevogen Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Tevogen Bio's return on equity of 0.00% beat Vyome's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -468.32% Vyome -3,024.84% -197.33% -138.14%

Does the media refer more to TVGN or HIND?

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Tevogen Bio's average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BKHA or HIND?

Vyome has a consensus price target of $9.25, indicating a potential upside of 360.20%. Given Vyome's stronger consensus rating and higher possible upside, analysts clearly believe Vyome is more favorable than Black Hawk Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Hawk Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vyome 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better valuation and earnings, BKHA or HIND?

Black Hawk Acquisition has higher earnings, but lower revenue than Vyome. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Hawk Acquisition N/A N/A N/A N/A N/A Vyome $320K 44.09 -$10.26M -$3.37 N/A

Does the media refer more to BKHA or HIND?

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 1 articles in the media. Black Hawk Acquisition's average media sentiment score of 0.35 beat Vyome's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Black Hawk Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vyome 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vyome (HIND) Competitors

$2.01 +0.06 (+3.08%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.10 +0.09 (+4.23%)

As of 09/23/2026 07:30 PM Eastern

Compare

HIND vs. IMA, APLM, ELTX, TVGN, and BKHA

Should you buy Vyome stock or one of its competitors? Vyome's main competitors and comparable companies include ImageneBio (IMA), Apollomics (APLM), Elicio Therapeutics (ELTX), Tevogen Bio (TVGN), and Black Hawk Acquisition (BKHA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vyome compare to ImageneBio?

Vyome (NASDAQ:HIND) and ImageneBio (NASDAQ:IMA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, Vyome and Vyome both had 1 articles in the media. Vyome's average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImageneBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImageneBio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. ImageneBio's return on equity of -38.99% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
ImageneBio	N/A	-38.99%	-34.84%

Vyome has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

Vyome currently has a consensus price target of $9.25, suggesting a potential upside of 360.20%. ImageneBio has a consensus price target of $29.00, suggesting a potential upside of 495.73%. Given ImageneBio's higher possible upside, analysts clearly believe ImageneBio is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

22.1% of Vyome shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Vyome has higher earnings, but lower revenue than ImageneBio. ImageneBio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	44.09	-$10.26M	-$3.37	N/A
ImageneBio	$800K	69.06	-$45.35M	-$4.58	N/A

Summary

ImageneBio beats Vyome on 8 of the 15 factors compared between the two stocks.

How does Vyome compare to Apollomics?

Vyome (NASDAQ:HIND) and Apollomics (NASDAQ:APLM) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Vyome had 1 more articles in the media than Apollomics. MarketBeat recorded 1 mentions for Vyome and 0 mentions for Apollomics. Vyome's average media sentiment score of 0.00 equaled Apollomics'average media sentiment score.

Company	Overall Sentiment
Vyome	Neutral
Apollomics	Neutral

22.1% of Vyome shares are held by institutional investors. Comparatively, 19.1% of Apollomics shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vyome presently has a consensus price target of $9.25, indicating a potential upside of 360.20%. Given Vyome's stronger consensus rating and higher possible upside, equities analysts clearly believe Vyome is more favorable than Apollomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Apollomics' return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-3,024.84%	-197.33%	-138.14%
Apollomics	N/A	N/A	N/A

Vyome has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Apollomics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

Vyome has higher earnings, but lower revenue than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	44.09	-$10.26M	-$3.37	N/A
Apollomics	$8.50M	7.89	-$10.94M	N/A	N/A

Summary

Vyome beats Apollomics on 8 of the 13 factors compared between the two stocks.

How does Vyome compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Elicio Therapeutics had 2 more articles in the media than Vyome. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Vyome. Elicio Therapeutics' average media sentiment score of 0.34 beat Vyome's score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Elicio Therapeutics has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Vyome's return on equity of -197.33% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has higher revenue and earnings than Elicio Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Vyome	$320K	44.09	-$10.26M	-$3.37	N/A

Elicio Therapeutics presently has a consensus target price of $19.75, suggesting a potential upside of 956.15%. Vyome has a consensus target price of $9.25, suggesting a potential upside of 360.20%. Given Elicio Therapeutics' higher possible upside, equities analysts plainly believe Elicio Therapeutics is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elicio Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Vyome has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Summary

Elicio Therapeutics beats Vyome on 7 of the 13 factors compared between the two stocks.

How does Vyome compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

In the previous week, Tevogen Bio and Tevogen Bio both had 1 articles in the media. Tevogen Bio's average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vyome has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A
Vyome	$320K	44.09	-$10.26M	-$3.37	N/A

Tevogen Bio has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Vyome has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

22.1% of Vyome shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 1,188.49%. Vyome has a consensus target price of $9.25, indicating a potential upside of 360.20%. Given Tevogen Bio's higher probable upside, equities analysts clearly believe Tevogen Bio is more favorable than Vyome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tevogen Bio has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Tevogen Bio's return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-468.32%
Vyome	-3,024.84%	-197.33%	-138.14%

Summary

Vyome beats Tevogen Bio on 9 of the 13 factors compared between the two stocks.

How does Vyome compare to Black Hawk Acquisition?

Black Hawk Acquisition (NASDAQ:BKHA) and Vyome (NASDAQ:HIND) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

Black Hawk Acquisition has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market. Comparatively, Vyome has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, Black Hawk Acquisition and Black Hawk Acquisition both had 1 articles in the media. Black Hawk Acquisition's average media sentiment score of 0.35 beat Vyome's score of 0.00 indicating that Black Hawk Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Black Hawk Acquisition	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vyome	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

22.1% of Vyome shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Black Hawk Acquisition has a net margin of 0.00% compared to Vyome's net margin of -3,024.84%. Black Hawk Acquisition's return on equity of 0.00% beat Vyome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Hawk Acquisition	N/A	N/A	N/A
Vyome	-3,024.84%	-197.33%	-138.14%

Vyome has a consensus price target of $9.25, indicating a potential upside of 360.20%. Given Vyome's stronger consensus rating and higher possible upside, analysts clearly believe Vyome is more favorable than Black Hawk Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Hawk Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vyome	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Black Hawk Acquisition has higher earnings, but lower revenue than Vyome.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Hawk Acquisition	N/A	N/A	N/A	N/A	N/A
Vyome	$320K	44.09	-$10.26M	-$3.37	N/A

Summary

Vyome beats Black Hawk Acquisition on 7 of the 11 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.69M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.60	13.88	274.02	25.69
Price / Sales	44.09	1,311.41	633.28	76.04
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	3.00	15.30	10.44	6.32
Net Income	-$10.26M	-$22.82M	$3.49B	$359.73M
7 Day Performance	2.55%	-1.71%	-0.66%	0.17%
1 Month Performance	-10.27%	-6.17%	-3.16%	-3.27%
1 Year Performance	-63.19%	30.64%	15.15%	5.58%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	2.4551 of 5 stars	$2.01 +3.1%	$9.25 +360.2%	N/A	$13.69M	$320K	N/A	18
IMA ImageneBio	3.0943 of 5 stars	$4.93 +0.2%	$29.00 +488.2%	-38.8%	$55.85M	$800K	N/A	18	Gap Up
APLM Apollomics	1.1477 of 5 stars	$21.88 -8.9%	N/A	+25.1%	$52.75M	$8.50M	N/A	15	Gap Down
ELTX Elicio Therapeutics	2.5615 of 5 stars	$1.77 -11.1%	$19.75 +1,015.8%	-83.2%	$52.30M	N/A	N/A	N/A	News Coverage Positive News Gap Down
TVGN Tevogen Bio	1.0293 of 5 stars	$7.80 +0.6%	$100.00 +1,182.1%	-80.6%	$50.46M	N/A	N/A	3	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors